CJC-1295

CJC-1295 is a synthetic 29–amino acid analog of growth hormone–releasing hormone (GHRH) designed to stimulate the pituitary gland to release endogenous growth hormone (GH). It represents the shortest functional fragment of GHRH capable of activating somatotroph cells, which are responsible for GH production.

The peptide contains four amino acid substitutions compared to native GHRH. These modifications are theorized to enhance stability, receptor affinity, and resistance to enzymatic degradation, resulting in a longer functional duration than natural GHRH while preserving physiological, pulsatile GH release.

By binding to GHRH receptors, CJC-1295 is believed to activate intracellular signaling pathways involving G-proteins and secondary messengers such as cAMP, which may promote GH gene expression. Increased GH secretion may subsequently elevate insulin-like growth factor-1 (IGF-1) levels, a hormone associated with protein synthesis, tissue growth, and cellular regeneration.

CJC-1295 has been studied for its potential role in lean muscle support, fat metabolism, bone and connective tissue maintenance, and sleep-related neuroendocrine function. Due to its modified structure, it is reported to have a longer half-life (~30 minutes) than native GHRH.

CJC-1295 is intended for research and laboratory purposes only.